Solutions for optimal care and research for children and adolescents with extremely rare cancers developed within the Joint Action for Rare Cancers (JARC)
EJC Paediatric Oncology, ISSN: 2772-610X, Vol: 2, Page: 100130
2023
- 1Citations
- 4Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Most Recent News
Reports Summarize Cancer Study Results from Clinical Hospital Center [Solutions for optimal care and research for children and adolescents with extremely rare cancers developed within the Joint Action for Rare Cancers (JARC)]
2024 JAN 01 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Fresh data on cancer are presented in a new report.
Article Description
Very rare cancers in children and adolescents pose a unique challenge for optimal care and research. Due to their rarity and diversity, there is a lack of standardized treatments and limited data to guide clinical decision-making. This paper aims to provide solutions for addressing these challenges through a multidisciplinary approach involving clinicians, researchers, and patient advocates. In recent years, members of the European Cooperative Study Group for Paediatric Rare Tumors (EXPeRT) and members of the European Society of Pediatric Oncology (SIOPE) clinical council worked within the EU Joint Action on Rare Cancers (JARC) and the Paed Can European Reference Network (ERN) on solutions to improve the care and research in the field. This includes a better classification, more financial resources, higher awareness and support by stakeholders, an international database, as well as harmonized diagnostic and therapeutic guidelines. Further research projects in the field of molecular biology, a better collaboration between medical oncologists and pediatricians, and a general strategy to facilitate access to modern therapies are urgently needed.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2772610X23001289; http://dx.doi.org/10.1016/j.ejcped.2023.100130; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85190525898&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S2772610X23001289; https://dx.doi.org/10.1016/j.ejcped.2023.100130
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know